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Previously, we have shown that a mutation in the mito-
chondrial DNA–encoded tRNALeu(UUR) gene is associat-
ed with type 2 diabetes. One of the consequences of this
mutation is a reduced aminoacylation of tRNALeu(UUR).
In this study, we have examined whether variants in the
leucyl tRNA synthetase gene (LARS2), involved in ami-
noacylation of tRNALeu(UUR), associate with type 2 dia-
betes. Direct sequencing of LARS2 cDNA from 25 type 2
diabetic subjects revealed eight single nucleotide poly-
morphisms. Two of the variants were examined in 7,836
subjects from four independent populations in the Neth-
erlands and Denmark. A 109 g/a variant was not asso-
ciated with type 2 diabetes. Allele frequencies for the
other variant, H324Q, were 3.5% in type 2 diabetic and
2.7% in control subjects, respectively. The common odds
ratio across all four studies was 1.40 (95% CI 1.12–
1.76), P  0.004. There were no significant differences
in clinical variables between carriers and noncarriers.
In this study, we provide evidence that the LARS2 gene
may represent a novel type 2 diabetes susceptibility
gene. The mechanism by which the H324Q variant en-
hances type 2 diabetes risk needs to be further estab-
lished. This is the first report of association between an
aminoacyl tRNA synthetase gene and disease. Our re-
sults further highlight the important role of mitochon-
dria in glucose homeostasis. Diabetes 54:1892–1895, 2005
Previously, we have shown that an A3243G mutationin the mitochondrial DNA–encoded tRNALeu(UUR)gene is associated with maternally inherited dia-betes and deafness (1,2). Carriers of the 3243
mutation have a reduced glucose-stimulated insulin se-
cretion. Biochemical studies indicate that mutant mito-
chondrial tRNALeucine is less efficiently aminoacylated in
comparison with the wild-type tRNA (2). Furthermore, it
has been shown that there is an altered balance between
mitochondrial and nuclear-encoded proteins in mutant
mitochondria, resulting in mitochondrial dysfunction (2).
In this study, we have examined whether variation in the
nuclear-encoded mitochondrial leucyl tRNA synthetase
gene (LARS2) is associated with type 2 diabetes. The
product of the LARS2 gene is the leucyl tRNA synthetase
protein (LeuRS, EC 6.1.1.4), which catalyzes the charging
of tRNALeu(UUR) with leucine, an essential step in protein
synthesis. Subjects (n  7,836) participating in this study
were recruited from four independent population samples
in the Netherlands and Denmark to allow independent
replication of association results.
RESEARCH DESIGN AND METHODS
Subjects participating in the association studies were selected from four
independent study populations in the Netherlands and Denmark. The first
cohort consisted of 547 participants of the Hoorn study (3), a population-
based study in the Netherlands. Subjects were classified as either type 2
diabetic subjects (n  211, aged 65  8 years, 48% male) or glucose-tolerant
control subjects (n 336, aged 60 7 years, 41% male) based on a fasting oral
glucose tolerance test (OGTT) according to World Health Organization
criterion. The second Dutch cohort is the ERGO (Rotterdam) study (4). All
subjects are aged 55 years, and nondiabetic subjects underwent a fasting
OGTT according to World Health Organization criteria. In total, 457 type 2
diabetic subjects (aged 71  9 years, 44% male) and 457 glucose-tolerant
control subjects (aged 64  5 years, 46% male) were randomly selected from
the total cohort (n  7,983).
Furthermore, we genotyped two case-control study samples from Den-
mark, DK1 and DK2. DK1 was a group of unrelated type 2 diabetic patients
recruited from the Steno Diabetes Center and a group of unrelated normal
glucose–tolerant (NGT) subjects sampled at random through public registers
at the Steno Diabetes Center and the Research Centre for Prevention and
Health (5). In the group of diabetic patients (n  706, 48% male), the age was
59  10 years and 57  10 years for NGT participants (n 514, 46% male) (5).
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DK2 consisted of unrelated type 2 diabetic patients recruited from the Steno
Diabetes Center and the Research Centre for Prevention and Health (n  654,
aged 54 10 years, 42% male) and a group of unrelated NGT subjects sampled
from the prospective Inter99 study at the Research Centre for Prevention and
Health (n  4,501, aged 45  8 years, 47% male) (6,7). All control subjects
participating in the Danish studies underwent a fasting OGTT according to
World Health Organization criteria.
Type 2 diabetic subjects were significantly older in all populations (all P 
0.01). Questionnaires were used to obtain other relevant information. All
participants were Caucasian whites by self-report. Informed written consent
was obtained from all subjects before participation. The study was approved
by the appropriate medical ethical committees and was in accordance with
the principles of the Declaration of Helsinki.
LARS2 sequencing. The LARS2 gene is mapped to the chromosome 3p21.3
region and spans 160 kb. Its 22 exons encode a 903 aa protein (LocuslinkID
23395). Total RNA was isolated from leukocytes and/or pancreas tissue (n 
7) from 25 Dutch type 2 diabetic subjects using standard procedures.
First-strand cDNA was made from these RNA samples using a first-strand
cDNA synthesis kit (Invitrogen, Carlsbad, CA). The LARS2 gene was amplified
in two overlapping segments (primer sequences and assay conditions avail-
able on request). The resulting segments encompassing 2,905 bp of the coding
region, including 159 bp of the promoter region, were subsequently sequenced
on an automated sequencer (Applied Biosystems, Foster City, CA). Haplo-
types of the identified single nucleotide polymorphisms (SNPs) (allele fre-
quency, 2.5%) were calculated using the Phase Program (8).
Genotyping. Two SNPs in the coding region of the LARS2 gene were studied
in further detail for association with type 2 diabetes and related quantitative
variables like circulating glucose and insulin levels during an OGTT. The first
SNP (g/a) was located at position 109 in the promoter area. A 197-bp
fragment surrounding the SNP was amplified using a mismatch primer. The
PCR fragment was cleaved with the restriction enzyme MspA1I, resulting in
fragments of 178 and 19 bp in the case of the wild-type sequence and 197 bp
in the case of the mutant sequence after separation on a 4% agarose gel.
The second SNP is a coding SNP located in exon 10. The C to A variant
changes a histidine at position 324 to glutamine (H324Q). Two different assays
were developed for genotyping this SNP. The first method was a restriction
fragment–length polymorphism–based method. The genomic region sur-
rounding the SNP was amplified using a mismatch primer introducing an
MspA1I site when the C allele is present. Primer sequences for both assays are
available on request. The second genotyping method for this SNP was based
on Taqman SNP genotyping technology (Applied Biosystems, Foster City,
CA). Primer and probe design was performed by the manufacturer (sequences
available on request), and reactions were done according to the manufactur-
ers’ protocol. This method was applied to all samples tested in this study
including sufficient replication and control samples. A replication sample of
1,500 Dutch samples using the restriction fragment–length polymorphism–
based method did not identify any mismatches. Furthermore, the accuracy of
both measures was further confirmed by direct sequencing of an additional 40
samples.
Overexpression and purification of wild-type and mutant leucyl tRNA
synthetase. The wild-type mature enzyme of 864 amino acid residues
(39LeuRS) was overexpressed in the BL21-Codonplus(DE3)RIL strain as
described (9). A human cDNA clone containing this His-tagged NH2-terminally
truncated LeuRS was obtained from M.P. King (10). The enzyme was purified
using nickel affinity chromatography as described (9). Furthermore, we have
made a construct with the H324Q polymorphism for production and purifica-
tion of the mutant enzyme (cloning details available on request).
Aminoacylation and editing reactions. Aminoacylation properties of the
wt and H324Q mutant enzymes were determined by measuring [3H]-leucine
incorporation according to a previously described method (9), using either
total bovine tRNA and/or human mitochondrial RNA as the tRNA source.
Furthermore, we have analyzed the mischarging rate of both enzymes using
several noncognate [3H]-labeled amino acids including [3H]-isoleucine (11). A
priori power calculations have shown that we should be able to detect
differences 10–15%.
Statistical analyses. Hardy-Weinberg equilibrium was tested in all cohorts
before further analysis. Differences in allele frequencies were tested by
Fisher’s exact tests. Since testing of the homogeneity of the population-
specific odds ratios revealed no significant differences, a common odds ratio
was calculated using a Mantel-Haenszel test. Differences in clinical variables
were tested by linear regression analysis, with adjustment for age, sex, and
BMI. Variables were log transformed before analysis, if necessary. The
statistical software packages SPSS 10.0 (SPSS, Chicago, IL) and StatXact 6.0
(Cytel, Cambridge, MA) were used.
RESULTS
Sequencing of the LARS2 cDNA, including 159 bp of the
promoter region in 25 type 2 diabetic subjects, revealed
eight different SNPs (Fig. 1). We did not find aberrant
splicing in any of the samples investigated. Haplotype
analysis using four SNPs with allele frequencies 2.5%
suggests at least six different haplotypes (frequency 4%).
Two variants (109 g/a and H324Q) potentially affecting
gene function were subsequently investigated in more
detail. Double heterozygous subjects were not found, and
haplotype and linkage disequilibrium analyses suggest that
the two SNPs are present on different haplotypes and
haploblocks (D  1, r2  0.013; Fig. 1).
Genotype distributions for both SNPs in the different
cohorts were all in Hardy-Weinberg equilibrium. The 109
g/a variant was tested for association in the two Dutch
cohorts. Allele frequencies were 31.3 and 32.6% for control
(n  329) and type 2 diabetic (n  215) subjects in the
Hoorn study (P  0.5) and 26.0 and 30.3% for control (n 
263) and type 2 diabetic (n  200) subjects in the ERGO
study (P  0.2). Combined analysis of both data sets after
testing the homogeneity of the population-based odds
ratios revealed no significant difference resulted in a
common odds ratio of 1.13 (95% CI 0.93–1.38, P  0.2).
Furthermore, we observed no association of this SNP
with relevant anthropometric or biochemical variables
obtained during OGTT (data not shown). There was also
no obvious association with LARS2 mRNA expression
levels, as measured during a real-time quantitative PCR
experiment on total RNA samples from type 2 diabetic
subjects (n  25 including 8 carriers).
The H324Q variant was examined in all four popula-
tions. Allele frequencies for each of the samples are given
in Table 1. Significant association between the gene vari-
ant and type 2 diabetes was present in the Hoorn cohort
(P  0.04, Table 1). Furthermore, there was a nonsignifi-
cant but identical trend toward association in all other
cohorts (Table 1). Analysis of the genotype distributions
FIG. 1. Locations of SNPs in LARS2 cDNA. Exon structure is given in black and white (noncoding [parts of] exons are shaded). Those SNPs
present in the National Center for Biotechnology Information (NCBI) dbSNP database are indicated below the map. The haploblock structure is
depicted below the exon structure based on HAPMAP data. Boxed SNPs are examined for association with type 2 diabetes. Corresponding dbSNP
numbers are (if available) NA, NA, NA, rs7610357, rs2128361, rs11549809, rs2170549, and rs267220.
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and adjustment for differences in age and sex yielded very
similar results (supplementary Table 1 [available at http://
diabetes.diabetesjournals.org]).
A homogeneity test revealed that there was no signifi-
cant difference between the odds ratios, as obtained in the
four different independent cohorts (P 0.5). The common
odds ratio across all four studies was 1.40 (95% CI 1.12–
1.76, P  0.004), suggesting that this SNP is significantly
associated with type 2 diabetes in these European study
samples. If we removed the Hoorn cohort, which has the
largest odds ratio, from these analyses, the odds ratio was
hardly affected (1.33 [95% CI 1.05–1.69, P 0.02]); this was
also true if we excluded any of the other cohorts. Linear
regression analysis with adjustment for age, sex, and BMI
revealed no consistent associations between this SNP and
any of the clinical variables tested (Table 2). Furthermore,
there was no evidence for an impact on mRNA expression
levels (data not shown, 25 individuals tested including
3 carriers). In vitro analysis of aminoacylation and editing
properties using purified wild-type and 324Q mutant
LeuRS yielded identical results, indicating that in in vitro
tests the aminoacylation and editing properties are not
significantly affected by the polymorphism (data not
shown).
DISCUSSION
We provide evidence that a coding SNP in LARS2 associ-
ates with type 2 diabetes in a meta-analysis of four
independent study populations from the Netherlands and
Denmark. To our knowledge, this is the first report show-
ing association between variation in an (mitochondrial)
aminoacyl tRNA synthetase gene and disease. Previous-
ly, we have shown that a defect in the mitochondrial
tRNALeu(UUR) gene associates with diabetes and a defect in
aminoacylation. Together, this suggests that changes in
the biochemical pathways linked to mt-tRNALeu(UUR) pre-
dispose to the development of glucose intolerance.
The risk associated with this gene variant is in the same
order of magnitude as shown for the three well-replicated
disease-associated genes: KIR6.2, peroxisome prolifera-
tor–activated receptor , and the Calpain10 haplotypes
(odds ratio 1.2–1.4) (12), suggesting again that the contri-
bution of predisposing genes per gene is limited and most
likely only a combination of several diabetes risk genes in
combination with a detrimental lifestyle results in glucose
intolerance. This further implies that only studies with
sufficient statistical power will be able to track down and
confirm association between such variants and type 2
diabetes.
It is difficult to predict whether this His-to-Gln mutation,
present at the surface of the editing domain, affects its
function. The editing domain is involved in the repair of
mischarged tRNAs, thereby keeping error rates in the
synthesis of proteins low. Functional in vitro tests exam-
ining aminoacylation and mischarging of the tRNA leucine
have not shown major differences. However, additional in
vitro and in vivo studies are needed to further elucidate
the precise functional impact of this protein variant. Since
TABLE 1
Allele frequencies for the H324Q (C3A) SNP in LARS2 in four different cohorts
Cohort
NGT Type 2 diabetes
P
Odds ratio
(95% CI)C A C A
Hoorn study 659 13 (0.019) 404 18 (0.043) 0.04 2.26 (1.10–4.66)
ERGO (Rotterdam) study 889 25 (0.027) 879 35 (0.038) 0.19 1.42 (0.84–2.39)
DK1, Steno case-control study 1,005 23 (0.022) 1,373 39 (0.028) 0.44 1.24 (0.74–2.10)
DK2, Inter99 case-control study 8,746 256 (0.028) 1,259 49 (0.037) 0.08 1.33 (0.97–1.82)
Common odds ratio — — — — 0.004 1.40 (1.12–1.76)
Data are total number (fraction of total number), unless otherwise indicated. P values were calculated using Fisher exact tests.
TABLE 2
Clinical characteristics of NGT subjects in the different study populations in relation to LARS2 His324Gln polymorphism
Hoorn study ERGO study DK2, Inter99 study
HH HQ 	 QQ HH HQ 	 QQ HH HQ 	 QQ
n 323 13 432 25 4,248 253
Age (years) 60  7 61  5 64  5 66  5* 45.2  7.8 44.6  7.7
Sex (male/female) 128/195 4/9 238/194 11/14 1,964/2,284 130/123
BMI (kg/m2) 26.1  3.0 25.7  2.6 25.9  3.2 25.2  4.1 25.5  4.1 25.3  3.7
HbA1c (%) 5.5  0.4 5.2  0.4 5.8  0.5 5.8  0.7 5.8  0.4 5.7  0.4
Fasting glucose (mmol/l) 5.4  0.5 5.1  0.4 5.4  0.4 5.4  0.4 5.3  0.4 5.3  0.4
2-h glucose (mmol/l) 5.2  1.3 5.1  1.3 5.3  1.1 5.4  1.1 5.5  1.1 5.5  1.2
Fasting insulin (pmol/l) 79  36 71  16 69  34 69  32 37  23 39  24
2-h insulin (pmol/l) NA NA 60  50 77  56 168  131 164  124
HOMA-IR 19.0  9.8 16.2  3.7 17.0  8.8 16.9  9.0 8.9  5.7 9.2  5.7
Cholesterol (mmol/l) 6.6  1.1 6.4  1.1 6.6  1.0 6.3  1.2 5.4  1.0 5.3  1.0
HDL (mmol/l) 1.33  0.34 1.50  0.65 1.34  0.33 1.31  0.37 1.46  0.40 1.40  0.37†
Triglycerides (mmol/l) 1.41  0.67 1.38  0.58 1.48  0.62 1.70  1.03 1.19  0.95 1.14  0.79
Free fatty acids (mmol/l) 0.58  0.21 0.55  0.17 0.29  0.09 0.34  0.12* NA NA
Data are means  SD. Three QQ homozygotes were detected in the DK2 cohort. P values were obtained after general linear regression
(SPSS), with age and BMI as covariates and sex and genotype as fixed factors. *P 0.01, †P 0.05. HOMA-IR, homeostasis model assessment
of insulin resistance.
THE LARS2 GENE AND NIDDM SUSCEPTIBILITY
1894 DIABETES, VOL. 54, JUNE 2005
we have studied only two SNPs in detail, it might be that
the H324Q variant is merely reflecting linkage disequilib-
rium with another unknown causative variant in this gene
or a nearby-located gene at the same locus. Further, more
detailed studies of this gene locus will be needed to
replicate and fully examine the nature of the observed
association between the H324Q variant and type 2 diabe-
tes.
In conclusion, we report the association of an amino
acid polymorphism in the leucyl tRNA synthetase gene and
type 2 diabetes in a combined analysis of four independent
study populations in the Netherlands and Denmark. To our
knowledge, this is the first report showing association
between variation in an aminoacyl tRNA synthetase gene
and disease, and it further highlights the importance of
correct mitochondrial function in glucose homeostasis
(1,13–15).
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